The former one accounts for around 15% of BC patients and possesses aggressive clinical features and results in a poor prognosis until the appearance of anti-HER-2 monoclonal antibody (trastuzumab and pertuzumab, etc.), which lifts response rate and improvs survival6–9. This evidence concerns the gene ERBB2 and breast cancer.